Description

Product Description

Pomalidomide is a synthetic derivative of thalidomide designed to enhance immunomodulatory potency while reducing off-target effects. Structurally classified as an imidazo[4,5-d]isoindole-1,3-dione, it is one of the key compounds in the IMiD (immunomodulatory drug) family, which includes thalidomide and lenalidomide. These compounds act as cereblon (CRBN) modulators, influencing protein ubiquitination and degradation processes that regulate immune and hematopoietic cell activity.

Chemical and Structural Characteristics

The molecular structure of Pomalidomide contains a glutarimide ring fused to a phthalimide moiety. This configuration enables interaction with the cereblon (CRBN) protein, part of the E3 ubiquitin ligase complex. By binding to CRBN, Pomalidomide alters substrate specificity, leading to targeted degradation of transcription factors such as Ikaros (IKZF1) and Aiolos (IKZF3), which are key regulators of B- and T-cell development.

Pomalidomide is chemically represented by the molecular formula C13H11N3O4 and a molecular weight of 273.25 g/mol. It appears as a white to off-white crystalline powder and is sparingly soluble in water but soluble in DMSO, DMF, and ethanol. Laboratory formulations often use DMSO stock solutions for in vitro assays.

Applications in Research

Pomalidomide is widely applied in preclinical and molecular research for its multifaceted effects on immune function, angiogenesis, and cytokine production. Major research applications include:

1. Cytokine Modulation Studies
   Pomalidomide upregulates interleukin-2 (IL-2) and interferon-gamma (IFN-γ) while downregulating tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This dual activity provides an important experimental model for exploring cytokine balance and immunoregulation in cellular systems.

2. Immune Cell Signaling
   Laboratory studies utilize Pomalidomide to assess T-cell proliferation, natural killer (NK) cell activation, and modulation of costimulatory signaling. It is a valuable compound for mechanistic investigations into adaptive and innate immune responses.

3. Angiogenesis Inhibition Research
   Through its action on vascular endothelial growth factor (VEGF) pathways, Pomalidomide suppresses angiogenesis in cell-based assays. Researchers use it to explore endothelial signaling, microvessel formation, and tumor microenvironment regulation.

4. Hematologic and Oncology Mechanisms
   In preclinical research, Pomalidomide serves as a model compound for studying multiple myeloma biology and myelodysplastic syndromes (MDS). It enables examination of cereblon-dependent ubiquitination and degradation of oncogenic transcription factors.

5. Gene and Proteome-Level Investigations
   Modern omics platforms integrate Pomalidomide in high-throughput screening of protein–protein interactions and ubiquitin-dependent proteolysis. Its well-characterized mechanism provides reproducible outcomes for post-translational modification research.

Product Specifications

Mechanism of Action

Pomalidomide acts through a complex and highly regulated mechanism centered on modulation of the cereblon (CRBN) E3 ubiquitin ligase complex. Its action influences protein degradation, cytokine release, and cellular differentiation, making it a pivotal molecule in immune system research.

Cereblon Binding and E3 Ligase Modulation

Cereblon, the substrate receptor of the CRL4^CRBN complex, is the primary molecular target of Pomalidomide. Upon binding, Pomalidomide alters substrate specificity of the ligase complex, promoting the ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3). These transcription factors regulate the development of B and T lymphocytes. Their downregulation leads to increased IL-2 production and enhanced T-cell activation, which are hallmark effects of IMiD compounds.

Cytokine Regulation

Pomalidomide influences both pro-inflammatory and anti-inflammatory cytokine networks:

• Upregulated Cytokines: IL-2, IFN-γ (promotes T-cell proliferation and NK cell activity).

• Downregulated Cytokines: TNF-α, IL-6 (suppresses chronic inflammation and tumor-promoting signals).

This bidirectional modulation makes Pomalidomide a powerful tool for dissecting immune homeostasis and cytokine feedback loops.

Inhibition of Angiogenesis

Pomalidomide also inhibits angiogenesis by suppressing endothelial cell proliferation and migration. This occurs through downregulation of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Laboratory assays involving endothelial tube formation or chick chorioallantoic membrane (CAM) models frequently employ Pomalidomide as a reference inhibitor to quantify antiangiogenic activity.

Cell Cycle and Apoptosis Regulation

Beyond immune signaling, Pomalidomide affects cell cycle dynamics in hematologic cells. By promoting degradation of oncogenic transcription factors and interfering with NF-κB signaling, it induces cell cycle arrest and apoptosis in malignant cell lines. Researchers use these effects to model cell death pathways and to evaluate synergistic responses with other small molecules.

Mechanism of Action 

Cereblon-Dependent Protein Degradation and Transcriptional Reprogramming

Pomalidomide serves as a molecular glue, reshaping the substrate specificity of the CRL4^CRBN complex. By enabling the recruitment of specific transcription factors, it promotes their ubiquitination and subsequent degradation via the proteasome. This process alters transcriptional networks governing immune cell proliferation, differentiation, and cytokine production.

Notably, degradation of Ikaros (IKZF1) and Aiolos (IKZF3) enhances IL-2 expression by relieving transcriptional repression on the IL-2 promoter in activated T cells. This immunomodulatory axis forms the biochemical basis for Pomalidomide’s potency in immunological research.
In parallel, suppression of IRF4—a downstream effector of Ikaros family proteins—affects plasma cell survival and differentiation, which has critical implications in hematologic malignancy models.

Synergistic Pathway Studies

Pomalidomide has been reported to exhibit synergistic molecular interactions when combined with other agents in experimental systems:

• With Dexamethasone: Enhances apoptosis in malignant plasma cell lines.

• With Interferon-α: Promotes immune activation and cytokine release.

• With Proteasome Inhibitors: Expands research opportunities for dual-pathway modulation studies in proteostasis and cell death.

Researchers employ these combinations to dissect the integrated roles of ubiquitin–proteasome signaling, transcriptional regulation, and apoptosis in cell biology.

Side Effects

Pomalidomide’s side effects are primarily derived from its immunomodulatory and hematopoietic influences. While these are not observed in standard laboratory assays, understanding the biological impact of its mechanisms is important for responsible handling in research contexts.

1. Hematologic Impacts

Due to suppression of select bone marrow progenitor lineages, exposure in in vivo models may lead to changes in neutrophil or platelet counts. These effects are dose-dependent and reversible under controlled conditions.

2. Immune System Modulation

Excessive cytokine release can result in imbalanced immune responses in experimental systems. Elevated levels of IL-2 and IFN-γ may induce hyperactivation of T cells or NK cells, altering the baseline parameters of cell viability studies.

3. Off-Target Protein Degradation

Although cereblon-dependent targeting is specific, extended exposure or non-optimized concentrations can lead to unintended proteolysis of additional transcription factors. This necessitates precise titration in cell-based experiments.

4. Oxidative and Metabolic Stress

High doses of Pomalidomide in metabolic assays can elevate reactive oxygen species (ROS) levels, leading to transient oxidative stress. Laboratory safety protocols recommend monitoring these effects under controlled redox conditions.

All observed side effects are relevant to research evaluation only and do not represent clinical pharmacology. This compound is strictly intended for scientific study, not for human or veterinary use.

Keywords

Pomalidomide, CAS 19171-19-8, IMiD compound, immunomodulatory drug, cereblon modulator, cytokine research, angiogenesis inhibition, hematologic research, thalidomide analogue, small-molecule immunoregulator, protein degradation, E3 ligase, high purity compound, laboratory-grade material, research chemical supplier China, peptide wholesale supplier, OEM small-molecule manufacturer, bulk chemical powder.

Shipping Guarantee

All Pomalidomide shipments are handled using validated cold-chain logistics to preserve compound integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We Pomalidomide ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (HPLC, MS, and NMR). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.

Payment Support

We Pomalidomide provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption and verified payment gateways to ensure confidentiality and fund security.

Disclaimer

All Pomalidomide products listed are intended for laboratory research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics and should not be administered to humans or animals. Researchers must handle all materials in accordance with institutional biosafety and chemical safety guidelines. The information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.